$Hims & Hers Health Inc.(HIMS)-To The Moon - Tiger Brokers Online Investing Community - To The Moon

$Hims & Hers Health Inc.(HIMS)$ Still have faith & conviction in Hims , my views as follows:--

Recent developments for Hims & Hers Health, Inc. (HIMS) in early 2026 are focused on a strategic pivot toward branded GLP-1 weight loss treatments, expansion into complex care, and international growth.

Here are the key, recent developments:

Partnership with Novo Nordisk (March 2026): Hims & Hers announced a collaboration with Novo Nordisk to sell branded GLP-1 medications—Wegovy and Ozempic—directly through its platform. This follows a previous legal dispute over compounded versions, effectively shifting the company toward offering branded, FDA-approved weight loss treatments.

GLP-1 Offerings and Pricing: The platform now offers Wegovy in various injection doses ($199/month) and as a pill, starting around $149 per month. The company also launched a new weight-loss membership program.

Expansion into "Hard Health" & Chronic Care: Hims & Hers is expanding beyond lifestyle drugs into more complex "hard health" categories, including cancer care and longevity treatments. They are also expanding their hormone health offerings, including menopause and testosterone care.

International Growth (ZAVA/Eucalyptus): The company is pushing for major European growth through its acquisition of ZAVA (UK, Germany, France, Ireland) and is looking into expansion in Canada. Reports also suggest significant expansion in Australia and Japan through the acquisition of Eucalyptus.

Hims & Hers Benefits & Tech Upgrades: The company launched "Hims & Hers Benefits," offering subscribers discounts on health services like Prenuvo whole-body MRI scans and Eight Sleep trackers. They are also integrating "Labs" (at-home diagnostics) and AI tools (MedMatch) to provide more personalized, data-driven care.

2026 Financial Guidance: The company issued strong 2026 guidance, projecting $2.7 billion to $2.9 billion in revenue, driven by its weight loss and specialty care expansions.

Modified in.04-01 10:21

Share your positions with us! This is a column where you can find the winning trades of our fellow tigers. There probably are a few potential opportunities that you may have overlooked.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

3

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":548702722844096,"tweetId":"548702722844096","gmtCreate":1774984922366,"gmtModify":1775010165624,"gmtUserModify":1775010083375,"author":{"id":4095252946433820,"idStr":"4095252946433820","authorId":4095252946433820,"authorIdStr":"4095252946433820","name":"Jason_LSE","avatar":"https://community-static.tradeup.com/news/3743bc1061440e3bac7c0e9716f3703a","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":13,"crmLevelSwitch":1,"currentWearingBadge":{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Published at least 3 PICK posts (or 10 IDEA posts) and, within the past 30 days, posted at least 1 PICK post (or 4 IDEA posts) and 1 comment","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.02.14","individualDisplayEnabled":0},"individualDisplayBadges":[{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Published at least 3 PICK posts (or 10 IDEA posts) and, within the past 30 days, posted at least 1 PICK post (or 4 IDEA posts) and 1 comment","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.01","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"}}],"fanSize":110,"starInvestorFlag":false},"themes":[{"themeId":"7516f9ef7e8042739b8597466da26fe7","categoryId":"7cf744760f454845a1870a05ea4e151d","name":"Winning Trades","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":7516f9ef7e8042739b8597466da26fe7}&rnconfig={\"headerBarHidden\": true}","description":"Share your positions with us! This is a column where you can find the winning trades of our fellow tigers. There probably are a few potential opportunities that you may have overlooked.","image":"https://community-static.tradeup.com/news/14c89d9656aedb9a4698e7996c575947"}],"images":[{"img":"https://community-static.tradeup.com/news/af6cf9c367a0b190b92cbbd60bbbe469","width":"584","height":"1113"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/af6cf9c367a0b190b92cbbd60bbbe469","width":"584","height":"1113"}],"title":"","html":"<html><head></head><body><p><a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$ </a> Still have faith &amp; conviction in Hims , my views&nbsp;as follows:--</p>\n<p>Recent developments for Hims &amp; Hers Health, Inc. (HIMS) in early 2026 are focused on a strategic pivot toward branded <a href=\"https://ttm.financial/J/showDialog/word_explain?id=1993149254180691968&amp;word=GLP-1\">GLP-1</a> weight loss treatments, expansion into complex care, and international growth.</p>\n<p>Here are the key, recent developments:</p>\n<p>Partnership with <a href=\"https://ttm.financial/J/showDialog/word_explain?id=1993157573763031040&amp;word=Novo Nordisk\">Novo Nordisk</a> (March 2026): Hims &amp; Hers announced a collaboration with Novo Nordisk to sell branded GLP-1 medications—<a href=\"https://ttm.financial/J/showDialog/word_explain?id=1993157757637550080&amp;word=Wegovy\">Wegovy</a> and <a href=\"https://ttm.financial/J/showDialog/word_explain?id=1993157675949285376&amp;word=Ozempic\">Ozempic</a>—directly through its platform. This follows a previous legal dispute over compounded versions, effectively shifting the company toward offering branded, <a href=\"https://ttm.financial/J/showDialog/word_explain?id=1993187250099609600&amp;word=FDA\">FDA</a>-approved weight loss treatments.</p>\n<p>GLP-1 Offerings and Pricing: The platform now offers Wegovy in various injection doses ($199/month) and as a pill, starting around $149 per month. The company also launched a new weight-loss membership program.</p>\n<p>Expansion into \"Hard Health\" &amp; Chronic Care: Hims &amp; Hers is expanding beyond lifestyle drugs into more complex \"hard health\" categories, including cancer care and longevity treatments. They are also expanding their hormone health offerings, including menopause and testosterone care.</p>\n<p>International <a href=\"https://ttm.financial/J/showDialog/word_explain?id=1993589237413109760&amp;word=Growth\">Growth</a> (ZAVA/Eucalyptus): The company is pushing for major European growth through its acquisition of ZAVA (UK, Germany, France, Ireland) and is looking into expansion in Canada. Reports also suggest significant expansion in Australia and Japan through the acquisition of Eucalyptus.</p>\n<p>Hims &amp; Hers Benefits &amp; Tech Upgrades: The company launched \"Hims &amp; Hers Benefits,\" offering subscribers discounts on health services like Prenuvo whole-body MRI scans and Eight Sleep trackers. They are also integrating \"Labs\" (at-home diagnostics) and AI tools (MedMatch) to provide more personalized, data-driven care.</p>\n<p>2026 Financial Guidance: The company issued strong 2026 <a href=\"https://ttm.financial/J/showDialog/word_explain?id=1993524664093532160&amp;word=guidance\">guidance</a>, projecting $2.7 billion to $2.9 billion in <a href=\"https://ttm.financial/J/showDialog/word_explain?id=1993245404275990528&amp;word=revenue\">revenue</a>, driven by its weight loss and specialty care expansions.&nbsp;</p><img src=\"https://community-static.tradeup.com/news/af6cf9c367a0b190b92cbbd60bbbe469\" tg-width=\"584\" tg-height=\"1113\"></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$ </a> Still have faith &amp; conviction in Hims , my views&nbsp;as follows:--</p>\n<p>Recent developments for Hims &amp; Hers Health, Inc. (HIMS) in early 2026 are focused on a strategic pivot toward branded <a href=\"https://ttm.financial/J/showDialog/word_explain?id=1993149254180691968&amp;word=GLP-1\">GLP-1</a> weight loss treatments, expansion into complex care, and international growth.</p>\n<p>Here are the key, recent developments:</p>\n<p>Partnership with <a href=\"https://ttm.financial/J/showDialog/word_explain?id=1993157573763031040&amp;word=Novo Nordisk\">Novo Nordisk</a> (March 2026): Hims &amp; Hers announced a collaboration with Novo Nordisk to sell branded GLP-1 medications—<a href=\"https://ttm.financial/J/showDialog/word_explain?id=1993157757637550080&amp;word=Wegovy\">Wegovy</a> and <a href=\"https://ttm.financial/J/showDialog/word_explain?id=1993157675949285376&amp;word=Ozempic\">Ozempic</a>—directly through its platform. This follows a previous legal dispute over compounded versions, effectively shifting the company toward offering branded, <a href=\"https://ttm.financial/J/showDialog/word_explain?id=1993187250099609600&amp;word=FDA\">FDA</a>-approved weight loss treatments.</p>\n<p>GLP-1 Offerings and Pricing: The platform now offers Wegovy in various injection doses ($199/month) and as a pill, starting around $149 per month. The company also launched a new weight-loss membership program.</p>\n<p>Expansion into \"Hard Health\" &amp; Chronic Care: Hims &amp; Hers is expanding beyond lifestyle drugs into more complex \"hard health\" categories, including cancer care and longevity treatments. They are also expanding their hormone health offerings, including menopause and testosterone care.</p>\n<p>International <a href=\"https://ttm.financial/J/showDialog/word_explain?id=1993589237413109760&amp;word=Growth\">Growth</a> (ZAVA/Eucalyptus): The company is pushing for major European growth through its acquisition of ZAVA (UK, Germany, France, Ireland) and is looking into expansion in Canada. Reports also suggest significant expansion in Australia and Japan through the acquisition of Eucalyptus.</p>\n<p>Hims &amp; Hers Benefits &amp; Tech Upgrades: The company launched \"Hims &amp; Hers Benefits,\" offering subscribers discounts on health services like Prenuvo whole-body MRI scans and Eight Sleep trackers. They are also integrating \"Labs\" (at-home diagnostics) and AI tools (MedMatch) to provide more personalized, data-driven care.</p>\n<p>2026 Financial Guidance: The company issued strong 2026 <a href=\"https://ttm.financial/J/showDialog/word_explain?id=1993524664093532160&amp;word=guidance\">guidance</a>, projecting $2.7 billion to $2.9 billion in <a href=\"https://ttm.financial/J/showDialog/word_explain?id=1993245404275990528&amp;word=revenue\">revenue</a>, driven by its weight loss and specialty care expansions.&nbsp;</p><img src=\"https://community-static.tradeup.com/news/af6cf9c367a0b190b92cbbd60bbbe469\" tg-width=\"584\" tg-height=\"1113\"></body></html>","text":"$Hims & Hers Health Inc.(HIMS)$ Still have faith & conviction in Hims , my views as follows:-- Recent developments for Hims & Hers Health, Inc. (HIMS) in early 2026 are focused on a strategic pivot toward branded GLP-1 weight loss treatments, expansion into complex care, and international growth. Here are the key, recent developments: Partnership with Novo Nordisk (March 2026): Hims & Hers announced a collaboration with Novo Nordisk to sell branded GLP-1 medications—Wegovy and Ozempic—directly through its platform. This follows a previous legal dispute over compounded versions, effectively shifting the company toward offering branded, FDA-approved weight loss treatments. GLP-1 Offerings and Pricing: The platform now offers Wegovy in various injection doses ($199/month) and as a pill, starting around $149 per month. The company also launched a new weight-loss membership program. Expansion into \"Hard Health\" & Chronic Care: Hims & Hers is expanding beyond lifestyle drugs into more complex \"hard health\" categories, including cancer care and longevity treatments. They are also expanding their hormone health offerings, including menopause and testosterone care. International Growth (ZAVA/Eucalyptus): The company is pushing for major European growth through its acquisition of ZAVA (UK, Germany, France, Ireland) and is looking into expansion in Canada. Reports also suggest significant expansion in Australia and Japan through the acquisition of Eucalyptus. Hims & Hers Benefits & Tech Upgrades: The company launched \"Hims & Hers Benefits,\" offering subscribers discounts on health services like Prenuvo whole-body MRI scans and Eight Sleep trackers. They are also integrating \"Labs\" (at-home diagnostics) and AI tools (MedMatch) to provide more personalized, data-driven care. 2026 Financial Guidance: The company issued strong 2026 guidance, projecting $2.7 billion to $2.9 billion in revenue, driven by its weight loss and specialty care expansions.","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/548702722844096","repostId":0,"isVote":1,"tweetType":1,"viewCount":199,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["HIMS"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":["晒单贴"],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":1684,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/548702722844096"}